Genmab — December 2024
-
Sukkeralf, det er oplyst flere gange på konferencer etc. Derfor forskellen på royalty procent I forhold til Rybrevant.
-
"The unprecedented durability of response seen in these data reinforce the potential of epcoritamab to become a core therapy for the treatment of multiple B-cell malignancies to benefit more patients," said Dr. Judith Klimovsky https://ml-eu.globenewswire.com/Resource/Download/5d2ab26b-5092-40d5-85c9-b653ab612acd
-
same from AbbVie
"More first-line treatments for diffuse large B-cell lymphoma are needed, especially for patients with aggressive disease markers that may impact the efficacy of current standard first-line therapies," said Lorenzo Falchi, M.D., Lymphoma Specialist, Department of Medicine, Memorial Sloan Kettering Cancer Center. "The durable responses observed in the study suggest significant potential for this first-line epcoritamab-based combination." -
Two Data Analyses From Clinical Trials Show Epcoritamab (DuoBody® CD3xCD20) Induces Durable Complete Reponses As Monotherapy and Combination Treatment in Patients With Diffuse Large B-Cell Lymphoma
Data presented at the 66th Annual Meeting and Exposition of the American Society of Hematology (ASH) NORTH CHICAGO, Ill., Dec. 9, 2024 /PRNewswire/ -- AbbVie (NYSE: ABBV) today announced new...
AbbVie News Center (news.abbvie.com)
-
Genmab har mandag offentliggjort positive langsigtede data fra to igangværende kliniske forsøg med antistoffet Epcoritamab til behandling af diffust storcellet B-celle lymfom.
Det fremgår af en meddelelse til fondsbørsen mandag aften.https://borsen.dk/nyheder/virksomheder/genmab-leverer-igen-lovende-data-fra-kraefthab?b_source=borsen&b_medium=row_0&b_campaign=list_1
-
-
Tak for den skarpe analyse nohope
-
Thomas Bowers fra Danske skifter til SEB. Ham har jeg nu alle dage synes godt om. Forhåbentlig fortsætter han sit syn på Genmab i den nye rolle. https://www.linkedin.com/posts/thomas-bowers-36394b4_jeg-er-glad-for-at-kunne-dele-at-jeg-starter-activity-7268918631357431808-ppx2?utm_source=share&utm_medium=member_android
-
AbbVie, Genmab tout Epkinly combos in earlier lines of non-Hodgkin lymphoma https://endpts.com/ash24-abbvie-genmab-tout-epkinly-combination-in-earlier-lines-of-non-hodgkin-lymphoma/
-
"Epkinly plus R-CHOP is being tested in an ongoing Phase 3 trial in the first-line setting. Allam Fakhoury, AbbVie’s therapeutic area lead in hematology oncology, told Endpoints News that the Phase 3 study in DLBCL is fully enrolled, and the company is “evaluating when the readout will be.” "
-
Epcoritamab + R-CHOP overcomes high total metabolic tumor volume in high-risk large B-cell lymphoma https://www.youtube.com/watch?v=bTNyW_82_Ks
-
0:15 / 1:07
Evaluating whether prior bendamustine exposure impacts the efficacy of epcoritamab in DLBCL https://www.youtube.com/watch?v=MFJdK1oXTns
-
@calliecoombsmd
Much lower severity CRS when using optimized schedule of epcoritamab and with promising response data - high rates of CR and uMRD! Median PFS 12.8 months. https://x.com/calliecoombsmd/status/1866254711781028086 -
-
@OncLive
·
10 u
Epcoritamab monotherapy in patients aged >75 with DLBCL who were anthracycline ineligible resulted in ORR 69% (CR 62%) with durable responses. https://x.com/OncLive/status/1866261702074941460 https://x.com/Fer_martinmoro/status/1866262621726576992
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind